

Industry Insight

INDIAN BULK DRUGS

July 2008

Cygnus

Business Consulting & Research Pvt.Ltd.

Knowledge Partner for Profitable Growth

4th & 5th Floors, Astral Heights, Road No. 1, Banjara Hills, Hyderabad-500034, India

Tel: +91-40-23430203-05, Fax: +91-40-23430201, E-mail: info@cygnusindia.com

Website: www.cygnusindia.com

Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by **Cygnus Business Consulting & Research Pvt Ltd** (Cygnus). While reasonable care has been taken in its preparation, Cygnus makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Cygnus will not be liable for any loss incurred by users from any use of the publication or contents

CONTENTS

1. Executive Summary	8
2. Highlights.....	10
3. Global Bulk drugs Market --- Market Overview.....	12
3.1. Introduction	12
3.1.1 Global Pharmaceutical Market.....	12
3.1.2 Leading Therapeutic Classes.....	13
3.1.3 Major Markets.....	15
3.2 Global Bulk Drugs Market	16
3.2.1 Major Segments	17
3.2.2 Classification of Bulk Drugs Manufacturers.....	18
3.2.3 Market Size	20
3.2.4 Major players	20
3.2.5 Industry Trends	23
3.2.6 Future outlook.....	27
4. Indian Bulk Drugs Market--- an Overview.....	28
4.1 Indian Pharmaceutical Market	28
4.1.1 Introduction	28
4.1.2 Major Therapeutic Segments.....	28
4.2 Indian Bulk Drugs.....	31
4.2.1 Introduction	31
4.2.2 Market Size	31
4.2.3 Major Bulk Drugs.....	32
4.2.4 Industry Associations.....	36
4.2.4.1 Bulk Drug Manufacturers' Association (India).....	36
4.2.4.2 Indian Drug Manufacturers Association (IDMA).....	37
4.2.4.3 Organization of Pharmaceutical Producers in India (OPPI)	
.....	38
4.3 Growth Trends	39
4.3.1 Mergers & Acquisitions	39
4.3.2 Indian Bulk Drugs Exports	42
4.3.3 Indian Bulk Drugs Imports.....	44
4.4 Future outlook	44

5. Growth Drivers	46
5.1 High Growth of Generics / Patent expiries	46
5.2 New Drug Developments.....	47
5.3 Contract Manufacturing.....	48
5.4 Overall Pharmaceutical Growth.....	50
5.5 Reduced Manufacturing cost.....	50
6. Industry Regulations	52
6.1 Regulatory Bodies.....	52
6.2 Pharmaceutical Policy-2002	52
6.3 National pharmaceutical policy 2006	52
6.4 Pricing of Scheduled Bulk Drugs.....	53
6.5 Indian Patent law	53
6.6 Labelling System in India	55
6.7 Intellectual Property Rights (IPR)	55
6.8 Trade Related Aspects of Intellectual Property Rights (TRIPS)	56
6.9 Bulk drugs prices come under NPPA lens	57
7. Issues & Challenges	59
7.1 Increasing Competition.....	59
7.2 Coping with Changing Disease Profile	59
7.3 Over Capacity	60
7.4 Undifferentiated Capabilities	60
7.5 Varying regulatory requirements lead to additional costs	61
7.6 Threat from China.....	61
8. Major Players.....	64
8.1 Aurobindo Pharma.....	64
8.1.1 Business Profile	64
8.1.2 Strategies.....	65
8.1.3 Financial Profile	66
8.1.4 SWOT Analysis	67
8.1.5 Outlook	68
8.2 Ranbaxy Laboratories.....	68
8.2.1 Business Profile	68
8.2.2 Strategies.....	69
8.2.3 Financial Profile	71

8.2.4 SWOT Analysis	71
8.2.5 Outlook	72
8.3 Dr. Reddy's Laboratories	72
8.3.1 Business Profile	72
8.3.2 Strategies.....	74
8.3.3 Financial Profile	75
8.3.4 SWOT Analysis	75
8.3.5 Outlook	76
8.4 Lupin Ltd.....	77
8.4.1 Business Profile	77
8.4.2 Strategies.....	78
8.4.3 Financial Profile	80
8.4.4 SWOT Analysis	80
8.4.5 Outlook	81
8.5 Matrix Laboratories.....	82
8.5.1 Business Profile	82
8.5.2 Strategies.....	83
8.5.3 Financial Profile	85
8.5.4 SWOT Analysis	85
7.5.3 Outlook	86
8.6 Cipla Ltd.....	86
8.6.1 Business Profile	86
8.6.2 Strategies.....	88
8.6.3 Financial Profile	88
8.6.4 SWOT Analysis	89
8.6.5 Outlook	90
8.7 Orchid Chemicals and Pharmaceuticals Ltd.	91
8.7.1 Business Profile	91
8.7.2 Strategies.....	92
8.7.3 Financial Profile	93
8.7.4 SWOT Analysis	93
8.7.5 Outlook	94
8.8 Divis laboratories.....	95
8.8.1 Business profile	95
8.8.2 Strategies.....	96
8.8.3 Financial Profile	96

8.8.4 SWOT Analysis	97
8.8.5 Outlook	98
8.9 Sun Pharmaceutical Industries Ltd.....	99
8.9.1 Business Profile	99
8.9.2 Strategies.....	100
8.9.3 Financial Profile	101
8.9.4 SWOT Analysis	101
8.9.5 Outlook	103
8.10 Ipca Laboratories Ltd.....	104
8.10.1 Business Profile	104
8.10.2 Strategies.....	105
8.10.3 Financial Profile	106
8.10.4 SWOT Analysis	106
8.10.5 Outlook.....	107
8.11 Dishman Pharmaceutical and Chemicals Ltd.....	108
8.11.1 Business Profile	108
8.11.2 Strategies.....	109
8.11.3 Financial Profile	110
8.11.4 SWOT Analysis	110
8.11.5 Outlook.....	111
8.12 Cadila Healthcare Ltd	112
8.12.1 Business Profile	112
8.12.2 Strategies.....	113
8.12.3 Financial Profile	114
8.12.4 SWOT Analysis	114
8.12.5 Outlook.....	115
8.13 Alembic Ltd	116
8.13.1 Business Profile	116
8.13.2 Strategies.....	117
8.13.3 Financial Profile	118
8.13.4 SWOT Analysis	118
8.13.5 Outlook.....	119
8.14. Glaxo SmithKline Pharmaceuticals Ltd.	120
8.14.1 Business Profile	120
8.14.2 Strategies.....	121
8.14.3 Financial Profile	122

8.14.4 SWOT Analysis	122
8.14.5 Outlook	123
8.15 Glenmark Pharmaceuticals Ltd.	124
8.15.1 Business Profile	124
8.15.2 Strategies.....	125
8.15.3 Financial Profile	126
8.15.4 SWOT Analysis	126
8.15.5 Outlook	127
8.16 Piramal Healthcare Limited (PHL)	127
8.16.1 Business Profile	127
8.16.2 Strategies.....	128
8.16.3 Financial Profile	129
8.16.4 SWOT Analysis	130
8.16.5 Outlook.....	130
8.17 Unichem Laboratories Ltd	132
8.17.1 Business Profile	132
8.17.2 Strategies.....	133
8.17.3 Financial Profile	134
8.17.4 SWOT Analysis	134
8.17.5 Outlook.....	135
8.18 Torrent Pharmaceuticals	135
8.18.1 Business Profile	135
8.18.2 Strategies.....	136
8.18.3 Financial Profile	137
8.18.4 SWOT Analysis	137
8.18.5 Outlook.....	138
8.19 Merck India Ltd.	140
8.19.1 Business Profile	140
8.19.2 Strategies.....	141
8.19.3 Financial Profile	141
8.19.4 SWOT Analysis	142
8.19.5 Outlook.....	142
8.20 Atul Ltd	143
8.20.1 Business Profile	143
8.20.2 Strategies.....	144
8.20.3 Financial Profile	144

8.20.4 SWOT Analysis	145
8.20.5 Outlook	146
9. Critical Success Factors.....	147
9.1 Low- Cost Manufacturing Skills	147
9.2 Striking Strategic Alliances (Mergers & Acquisitions)	147
9.3 Growing Experience with cGMP Compliance	148
9.4 Complex Synthesis Capabilities.....	148
9.5 Identifying New Opportunities Holds the Key for Generic Manufacturers.....	148
9.6 Indian Companies enter in to Global Cancer Drugs Market	149
9.7 Focus on New therapeutic Segments.....	150
9.8 Time the Market:	150
9.9 Accreditations.....	151
10. Future Outlook.....	152
Annexure 1: List of Abbreviations	154
Annexure 2: DMF filings by Indian companies	155
Annexure 3: List of Bulk Drugs Manufacturers in India	172
Annexure 4: List of Industry Organizations	177
Annexure 5: Bibilography.....	179

LIST OF CHARTS

- Chart 1: Global Pharmaceutical Market Value, 2002-2007
- Chart 2: Market Share by Differentiation, 2007
- Chart 3: Global Bulk Drugs Market Size, 2003-2007
- Chart 4: Indian Pharmaceutical Market, 2002-2007
- Chart 5: Major Therapeutic Segments, 2006-2007
- Chart 6: Vision 2010: Glimpse of Indian Pharmaceutical Market Future
- Chart 7: Estimated Indian Bulk Drugs Market
- Chart 8: Indian Pharmaceutical Exports
- Chart 9: Estimated Indian Bulk Drugs Exports
- Chart 10: Estimated Indian Bulk Drugs Imports
- Chart 11: Value of Patent Expiries, 2006-2010
- Chart 12: Global Contract Manufacturing Market, 2002-2011
- Chart 13: India & China DMF Filings
- Chart 14: Estimated Indian Bulk Drugs Market, 2006-2010E
- Chart 15: Estimated Indian Export and Import Trends, 2006-2010E

LIST OF TABLES

- Table 1: Leading Therapeutic Segments, 2007
- Table 2: Leading Brands, 2007
- Table 3: Major Markets, 2007
- Table 4: Market Segment
- Table 5: Global Major players
- Table 6: Global Mergers & Acquisition
- Table 7: Annual Production of Major Bulk Drugs
- Table 8: Mergers & Acquisition by Indian Companies
- Table 9: ANDA Filings by Indian Companies
- Table 10: R&D Expenditure (2006-07)
- Table 11: DMF Filings by Indian Companies
- Table 12: India's Advantages for Contract Manufacturing
- Table 13: Comparison between India and China